Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 13/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27704445 | 0.86 | POLB (0.41) | SIRT1POLBMEN1KMT2A | |
| SCHEMBL12501521 | 0.77 | SIRT1 (0.40) | SIRT1SIRT2POLBMEN1KMT2A | |
| SCHEMBL30946854 | 0.70 | NISCH (0.71) | NISCHPOLBMEN1KMT2A | |
| SCHEMBL2977327 | 0.70 | NISCH (0.71) | NISCHPOLBMEN1KMT2A | |
| SCHEMBL860446 | 0.70 | HPGD (0.59) | SIRT1SIRT2NISCHATM | |
| SCHEMBL29974170 | 0.70 | HPGD (0.59) | SIRT1SIRT2NISCHATM | |
| SCHEMBL442707 | 0.70 | ATM (0.50) | SIRT1SIRT2NISCHATMSIRT3 | |
| SCHEMBL9530592 | 0.69 | BRD4 (0.40) | NISCHPOLBMEN1KMT2A | |
| SCHEMBL20768161 | 0.69 | P2RY6 (0.33) | NISCH | |
| Hydrochloric Acid SCHEMBL17845907 | 0.69 | NISCH (0.69) | NISCHPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984967-B1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | IAF BIOCHEM INT (CA) | 2004-02-25 | — | — | EP | claimed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | claimed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | claimed |
| EP-1037633-B1 | ANTIVIRAL COMPOUNDS | IAF BIOCHEM INT (CA) | 2003-09-10 | — | — | EP | disclosed |
| US-6534520-B2 | Antiviral compounds | BIOCHEM PHARMA INC. (CA) | 2003-03-18 | — | — | US | disclosed |
| US-20010031765-A1 | Antiviral compounds | BIOCHEM PHARMA INC. | 2001-10-18 | — | — | US | disclosed |
| US-6255318-B1 | CYTOMEGLO VIRUS | BIOCHEM PHARMA INC. (CA) | 2001-07-03 | — | — | US | disclosed |
| EP-0984967-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC (CA) | 2000-03-15 | — | — | EP | disclosed |
| US-5945431-A | VIRICIDE | BIOCHEM THERAPEUTICS INCORPORATED (CA) | 1999-08-31 | — | — | US | disclosed |
| WO-1997034894-A1 | NAPHTHYRIDINE DERIVATIVES AND THEIR ANALOGUES INHIBITING CYTOMEGALOVIRUS | BIOCHEM PHARMA INC. (CA) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031765-A1 | Antiviral compounds | ZC3HAV1, IFNAR1, EIF2AK2 | SIRT1 999/4885SIRT2 1344/4885NISCH 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.